Evidence map›Paper›PMID 35724834›Full record

ArticleEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2022

Metformin and Cancer: Is This the End?

Emily J Gallagher, Nathan G Kase, Nina A Bickell, Derek LeRoith

Abstract readComment
PubMed Publisher
In one paragraph

Article in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Emily J GallagherDivision of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: emily.gallagher@mssm.edu.
Nathan G KaseDepartment of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York.
Nina A BickellTisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Population Health Science and Policy, Center for Health Equity and Community-Engaged Research, Icahn School of Medicine at Mount Sinai, New York, New York.
Derek LeRoithDivision of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsInsulin ResistanceMetforminNeoplasmsFemaleHumansHypoglycemic AgentsInsulinHypoglycemic AgentsInsulinMetforminbreast cancerinsulin resistanceMA.32metformin

Identifiers

PMID35724834

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.